$64.59
+0.52 (+0.81%)
Open$64.19
Previous Close$64.07
Day High$65.45
Day Low$63.68
52W High$91.00
52W Low$8.91
Volume—
Avg Volume3.60M
Market Cap3.87B
P/E Ratio—
EPS$-2.32
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-68.0% upside
Current
$64.59
$64.59
Target
$20.70
$20.70
$16.39
$20.70 avg
$27.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 372.50M | 351.85M | 301.99M |
| Net Income | -104,674,461 | -84,234,881 | -79,583,487 |
| Profit Margin | -28.1% | -23.9% | -26.4% |
| EBITDA | -120,858,001 | -107,157,018 | -93,330,324 |
| Free Cash Flow | -75,919,374 | -55,757,162 | -73,499,960 |
| Rev Growth | -6.8% | +18.4% | +6.2% |
| Debt/Equity | 0.83 | 0.74 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |